Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-25-059322
Filing Date
2025-04-28
Accepted
2025-04-28 16:15:15
Documents
18
Period of Report
2025-06-10

Document Format Files

Seq Description Document Type Size
1 DEF 14A atra-20250428.htm   iXBRL DEF 14A 1680661
2 GRAPHIC img122750870_0.jpg GRAPHIC 15801
3 GRAPHIC img122750870_1.jpg GRAPHIC 121478
4 GRAPHIC img122750870_2.jpg GRAPHIC 331645
5 GRAPHIC img122750870_3.jpg GRAPHIC 102329
6 GRAPHIC img122750870_4.jpg GRAPHIC 102780
  Complete submission text file 0000950170-25-059322.txt   4790854

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT atra-20250428.xsd EX-101.SCH 15714
20 EXTRACTED XBRL INSTANCE DOCUMENT atra-20250428_htm.xml XML 590612
Mailing Address 1280 RANCHO CONEJO BLVD THOUSAND OAKS CA 91320
Business Address 1280 RANCHO CONEJO BLVD THOUSAND OAKS CA 91320 805-623-4211
Atara Biotherapeutics, Inc. (Filer) CIK: 0001604464 (see all company filings)

EIN.: 460920988 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36548 | Film No.: 25880541
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)